RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:145

Hereditary breast and/or ovarian cancer syndrome

low confidenceDisorder

Publications

7,112

Trials

40

Interventional, condition-specific

Researchers

1,721

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A genetic condition characterized by susceptibility to breast and/or ovarian cancer. It can be defined using family history criteria, or through identification of germline pathogenic variants (GPVs) in clinically validated HBOC genes. However, the genetic basis of about half of clinical HBOC is currently unknown or unexplained by single-gene variants, and approximately half of individuals who harbour PVs in HBOC genes do not have a suggestive family history.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (8)

BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) · Hereditary Breast and Ovarian Cancer Syndrome · familial breast and ovarian cancer syndrome · familial breast/ovarian cancer (BRCA1, BRCA2) · hereditary breast and ovarian cancer · hereditary breast and ovarian cancer syndrome · hereditary breast ovarian cancer syndrome · hereditary breast/ovarian cancer (BRCA1, BRCA2)

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    7,112 matched papers (4,888 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    40 matched on ClinicalTrials.gov (7 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

7,112

7,112 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

7,112 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

4,888 in the last 10 years · low confidence

Phrase hits: 7,112 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,721

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Kobayashi Y7 papers · 2026

    Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.

    Papers in Europe PMC
  2. 02
    Masuda K7 papers · 2026

    Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.

    Papers in Europe PMC
  3. 03
    Seki T7 papers · 2026

    Center for Hereditary Breast and Ovarian Cancer Syndrome, Keio University Hospital, Tokyo, Japan.

    Papers in Europe PMC
  4. 04
    Goto Y6 papers · 2026

    Center for Hereditary Breast and Ovarian Cancer Syndrome, Keio University Hospital, Tokyo, Japan.

    Papers in Europe PMC
  5. 05
    Kim S6 papers · 2026

    Mo-Im Kim Nursing Research Institute, College of Nursing, Yonsei University, 03722, Seoul, South Korea. Electronic address: suekim@yuhs.ac.

    Papers in Europe PMC
  6. 06
    Misu K6 papers · 2026

    Center for Hereditary Breast and Ovarian Cancer Syndrome, Keio University Hospital, Tokyo, Japan.

    Papers in Europe PMC
  7. 07
    Nakamura K6 papers · 2026

    Center for Hereditary Breast and Ovarian Cancer Syndrome, Keio University Hospital, Tokyo, Japan.

    Papers in Europe PMC
  8. 08
    Ono I6 papers · 2026

    Center for Hereditary Breast and Ovarian Cancer Syndrome, Keio University Hospital, Tokyo, Japan.

    Papers in Europe PMC
  9. 09
    Ngeow J5 papers · 2026

    Cancer Genetics Service, Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.

    Papers in Europe PMC
  10. 10
    Yamada M5 papers · 2025

    Center for Hereditary Breast and Ovarian Cancer Syndrome, Keio University Hospital, Tokyo, Japan.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

40

interventional trials for this specific condition

40 interventional trials matched this specific condition name; 7 currently recruiting in our sample.

Data as of 27 July 2026

40 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 96.6th percentile).

low confidence · 96.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

40 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

18 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Hereditary breast and/or ovarian cancer syndrome" OR "BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC)" OR "Hereditary Breast and Ovarian Cancer Syndrome" OR "familial breast and ovarian cancer syndrome" OR "familial breast/ovarian cancer (BRCA1, BRCA2)" OR "hereditary breast and ovarian cancer" OR "hereditary breast ovarian cancer syndrome" OR "hereditary breast/ovarian cancer (BRCA1, BRCA2)"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Hereditary breast and/or ovarian cancer syndrome" OR "BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC)" OR "Hereditary Breast and Ovarian Cancer Syndrome" OR "familial breast and ovarian cancer syndrome" OR "familial breast/ovarian cancer (BRCA1, BRCA2)" OR "hereditary breast and ovarian cancer" OR "hereditary breast ovarian cancer syndrome" OR "hereditary breast/ovarian cancer (BRCA1, BRCA2)"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 40 interventional · 18 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (7112) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-26T12:38:30.725Z